Abeona Therapeutics Inc.

Healthcare · Biotechnology · United States

Last price 4.35 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 248.75M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platfor...